Ardelyx (ARDX) Accumulated Expenses (2013 - 2026)
Ardelyx posted quarterly Accumulated Expenses of $9.4 million for Q1 2026, down 78.05% year-on-year from $42.7 million in Q1 2025, and down 80.28% on a QoQ basis from $47.6 million in Q4 2025.
Ardelyx (ARDX) has 14 years of Accumulated Expenses data on file, last reported at $9.4 million in Q1 2026.
- For the quarter ending Q1 2026, Accumulated Expenses fell 78.05% year-over-year to $9.4 million; the trailing twelve-month figure through Mar 2026 stood at $9.4 million (down 78.05% YoY), and the FY2025 full-year result was $47.6 million, up 37.34% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $9.4 million, down from $47.6 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $47.6 million in Q4 2025 and bottomed at $6.8 million in Q1 2022.
- The 5-year median for Accumulated Expenses is $11.5 million (2024), against an average of $18.6 million.
- The widest annual swing landed in 2025, when Accumulated Expenses surged 289.76%; it then sank 78.05% in 2026.
- A 5-year view of Accumulated Expenses shows it stood at $7.5 million in 2022, then jumped by 99.27% to $15.0 million in 2023, then jumped by 130.32% to $34.6 million in 2024, then surged by 37.34% to $47.6 million in 2025, then tumbled by 80.28% to $9.4 million in 2026.
- The last three Accumulated Expenses figures came in at $9.4 million (Q1 2026), $47.6 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Ardelyx | 1.48 Bn | 1.25 Bn | 89.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.38 Mn |
| Dec 31, 2025 | 47.58 Mn |
| Sep 30, 2025 | 15.06 Mn |
| Jun 30, 2025 | 40.76 Mn |
| Mar 31, 2025 | 42.74 Mn |
| Dec 31, 2024 | 34.64 Mn |
| Sep 30, 2024 | 11.54 Mn |
| Jun 30, 2024 | 10.46 Mn |
| Mar 31, 2024 | 21.99 Mn |
| Dec 31, 2023 | 15.04 Mn |
| Sep 30, 2023 | 19.04 Mn |
| Jun 30, 2023 | 6.88 Mn |
| Mar 31, 2023 | 11.05 Mn |
| Dec 31, 2022 | 7.55 Mn |
| Sep 30, 2022 | 7.34 Mn |
| Jun 30, 2022 | 7.94 Mn |
| Mar 31, 2022 | 6.78 Mn |
| Dec 31, 2021 | 5.42 Mn |
| Sep 30, 2021 | 11.37 Mn |
| Jun 30, 2021 | 8.55 Mn |
| Mar 31, 2021 | 4.35 Mn |
| Dec 31, 2020 | 6.66 Mn |
| Sep 30, 2020 | 3.72 Mn |
| Jun 30, 2020 | 7.57 Mn |
| Mar 31, 2020 | 1.95 Mn |
| Dec 31, 2019 | 7.25 Mn |
| Sep 30, 2019 | 2.80 Mn |
| Jun 30, 2019 | 10.40 Mn |
| Mar 31, 2019 | 500,000.00 |
| Dec 31, 2018 | 3.60 Mn |
| Sep 30, 2018 | 9.97 Mn |
| Jun 30, 2018 | 2.20 Mn |
| Mar 31, 2018 | 1.62 Mn |
| Dec 31, 2017 | 3.23 Mn |
| Sep 30, 2017 | 2.72 Mn |
| Jun 30, 2017 | 2.60 Mn |
| Mar 31, 2017 | 1.86 Mn |
| Dec 31, 2016 | 3.16 Mn |
| Sep 30, 2016 | 2.23 Mn |
| Jun 30, 2016 | 4.20 Mn |
| Mar 31, 2016 | 2.74 Mn |
| Dec 31, 2015 | 311,000.00 |
| Sep 30, 2015 | 8.17 Mn |
| Jun 30, 2015 | 1.46 Mn |
| Mar 31, 2015 | 470,000.00 |
| Dec 31, 2014 | 780,000.00 |
| Sep 30, 2014 | 1.11 Mn |
| Jun 30, 2014 | 802,000.00 |
| Dec 31, 2013 | 100,000.00 |